Accretion Pharmaceuticals Limited is an India-based company. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of drugs, pharmaceutical products and related products. Its product portfolio includes five verticals, such as tablet, oral liquid, external preparation, capsule, and oral powder. Its products include Azithromycin 250 mg/500 mg, Ciprofloxacin 250/500 mg, Ketoconazole 200 mg, Levofloxacin 250mg/500 mg, Levofloxacin 250 mg+Ornidazole 500 mg, Itraconazole 100mg/200 mg (AS PELLETS), Ofloxacin 100mg + Metronidazole 200mg suspension, Aceclofenac 100mg+Paracetamol 325 mg, Deflazacort 6 mg, Ibuprofen 400mg/600mg, Mefenamic acid 250mg+Dicyclomine HCL 10mg, Nimesulide MD 100mg, Doxofylline 400 mg, Ibuprofen 100mg oral suspension, Montelukast 5mg/10mg, Cetirizine dihydrochloride 5mg/10mg, Omeprazole 20mg, Ondansetron 2 mg Syrup, and others.As of 9 Jun 2026, ACCRETION PHARMA LIMITED share price is ₹136.60. The stock opened at ₹136.60, compared to its previous close of ₹138.00. During today's trading session, ACCRETION PHARMA LIMITED share price moved in the range of ₹136.60 to ₹136.60, with an average price of ₹136.60 for the day. Looking at its last 52-week, the stock has touched a low of ₹136.60 and a high of ₹136.60. On the performance front, ACCRETION PHARMA LIMITED share price has increased by 49.03% over the last six months and is up 111.01% on a year-on-year basis.
The market capitalization of ACCRETION PHARMA LIMITED is ₹153 Crs, with a P/E ratio of 15.9 and a dividend yield of 0.00%.